In vivo

Organ on a chip
#CN Bio #Drug development #Drug screening #In vivo #Organ-on-a-chip #Organoids #SLAS

Organ-on-a-chip models in drug development

This paid-for advertorial by CN Bio appeared in DDW Volume 24 – Issue 2, Spring 2023 Despite advancements, the drug development process remains inefficient. Even with rigorous optimisation and validation, we face a 90% failure rate by the clinical phase1. Existing in vivo and in vitro models aren’t up to… Read More

#Exclusive Content

#Clinical trial #CRISPR #FDA #Gene editing #Gene therapy #In vivo #Intellia Therapeutics

FDA clears in vivo gene editing therapy for trials in US

The US Food and Drug Administration (FDA) has cleared Intellia Therapeutics’ Investigational New Drug (IND) application for NTLA-2002 for the treatment of hereditary angioedema (HAE).  Intellia is a clinical-stage genome editing company focused on developing potentially curative therapies using CRISPR-based technologies.   The decision will enable the company to include the… Read More

#News #Regulatory #Trending News

Organoids
#Drug development #Drug discovery #Drug screening #Gene editing #In vitro #In vivo #Organoids #Personalised medicine

Gene editing in organoids: accounting for complexity in drug discovery

Oksana Sirenko looks at the advantages and limitations of using organoids from human cell sources in drug development and drug screening.  The genome is the blueprint for life, consisting of genes made up of thousands of pairs of DNA bases. Altering one base pair can drastically change how the gene’s… Read More

#Exclusive Content

#Immunology #In vivo #Mouse models #T-Cells

Read the Top Five Benefits of a Cloud ELN

As experimental data becomes bigger and more complex, scientists are challenged to make discoveries faster, consistently document and analyse their work, and easily collaborate across an organisation and with external partners. Electronic lab notebooks (ELN) provide access to all collaborators 24/7, wherever they are and whether they are employees or… Read More

#Intelligence #Resources

#Immunology #In vivo #Mouse models #T-Cells

The latest MHC class I & II deficient in vivo platform humanised with PBMCs

This whitepaper, brought to you by The Jackson Laboratory will teach: The benefits of the JAX NSGTM-MHC I/II KO mouse platform humanised with pre-characterised PBMCs How this platform can support a wide range of immunological studies, especially those containing T cells responses The versatility of this platform to various research disciplines… Read More

#Intelligence #Resources

#In vivo

PerkinElmer expands in vivo instruments portfolio  

PerkinElmer has expanded its in vivo imaging portfolio with the launch of the Vega imaging system, an ultrasound platform that combines hands-free, automated technology with high-throughput capability to accelerate non-invasive research and drug development studies of cancer, liver and kidney disease, cardiology and more.   The Vega system … Read More

#News

#Cytokines #In vitro #In vivo #Research study #Whitepaper

White Paper: A new way to study cytokine release syndrome

An in vivo CRS Evaluation Study in humanised mouse models can deliver fast, reproducible, and translatable data about drug safety in just two weeks. A humanised mouse platform offers the unique ability to preclinically analyse a fully systemic response that involves human immune cells and surrounding tissues. Furthermore, the platform… Read More

#News #Trending News

#Biopharmaceuticals #Drug development #Drug discovery #Immunology / Virology & Vaccines #In vivo

Agreement to develop vaccines against cancer and infectious diseases 

Nykode Therapeutics (formerly Vaccibody) has entered into a license and collaboration agreement with Regeneron for the discovery, development and commercialisation of potential new vaccines for cancer and infectious diseases.  What is the structure of the agreement?  The agreement includes five programmes, three within cancer and two within infectious diseases. Read More

#News

#Biologics / Biotechnology #Covid-19 #HIV #In vivo #Therapeutics

Biotech start-up takes another stride toward flu cure 

Covimro, a British biotech start-up, has developed a food-grade compound which has demonstrated its efficacy against the flu virus in an animal model study carried out by A-IR Clinical Research and Pharmidex Pharmaceutical Services.  The in vivo testing analysed Covimro’s antiviral capability against an infection of Influenza A H3N2, a flu variant consistent with… Read More

#News #Start-up Zone

Doctor administering a vaccine to patient
#Drug delivery #Drug development #Gene therapy #In vivo

Collaboration expands reach in next generation vaccines

Gamma Biosciences has agreed to make a controlling investment in Mirus Bio for nucleic acid delivery based in Madison, Wisconsin. The transaction will support Mirus’ plans to expand good manufacturing practice (GMP) production and commercialisation of its flagship product TransIT VirusGEN for large scale manufacturing of AAV and LV-based viral… Read More

#News